5-aminopyrazole

structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Nitulescu, George Mihai: 1 article (11/2019)
2.	Olaru, Octavian Tudorel: 1 article (11/2019)
3.	Swanepoel, Bresler: 1 article (11/2019)
4.	Venables, Luanne: 1 article (11/2019)
5.	van de Venter, Maryna: 1 article (11/2019)
6.	Abdellatif, Khaled R A: 1 article (01/2016)
7.	Azouz, Amany A: 1 article (01/2016)
8.	Bakr, Rania B: 1 article (01/2016)

1.	Non-alcoholic Fatty Liver Disease 11/01/2022 - "We describe the synthesis of a series of 3-t-butyl 5-aminopyrazole p-substituted arylamides as inhibitors of serine-threonine25 (STK25), an enzyme implicated in the progression of non-alcoholic fatty liver disease (NAFLD). "
2.	Neoplasms (Cancer) 11/07/2019 - "Anti-Cancer Activity of a 5-Aminopyrazole Derivative Lead Compound (BC-7) and Potential Synergistic Cytotoxicity with Cisplatin against Human Cervical Cancer Cells."
3.	Edema (Dropsy) 01/01/2016 - "Compounds having pyrazolyl moiety in a hybrid structure with pyrazolo[3,4-d]pyrimidine scaffold (14a-d, 16 and 17) showed higher edema inhibition percentage activities (34-68%) and the 5-aminopyrazole derivative (14c, ED50 = 87.9 μmol/kg) was the most potent one > celecoxib (ED50 = 91.9 μmol/kg). "
4.	Uterine Cervical Neoplasms (Cancer of the Cervix) 11/07/2019 - "Anti-Cancer Activity of a 5-Aminopyrazole Derivative Lead Compound (BC-7) and Potential Synergistic Cytotoxicity with Cisplatin against Human Cervical Cancer Cells."